EX-99.1
3
ex99-1.txt
PRESS RELEASE DATED 5-30-08
Exhibit 99.1
CAVIT SCIENCES, INC. ANNOUNCES ASSET PURCHASE AGREEMENT
BOCA RATON, FL, MAY 30, 2008--CAVIT SCIENCES, INC. ("Cavit") (OTCBB: CVIT)
announced today that it completed an Asset Purchase Agreement with Alternecare
Health Products, Inc. ("ALTERNECARE(TM)") on May 28, 2008.
ALTERNECARE(TM) is an innovator and leader in combining rapid home diagnostics
with therapeutic nutraceutical based solutions, has penetrated the retail market
in the US and has initiated the process to establish itself in the e-commerce
marketplace. Cavit acquired ALTERNECARE(TM)'s inventory, customer lists,
existing relationships, trademark and website.
Most importantly, Cavit acquired the consulting services of Ismael Gonzalez,
ALTERNECARE(TM)'s President. Ismael has over 15 years of management experience
in the natural products industry. He has held business development roles with
top companies ranging from manufacturing to distribution. His business
development expertise will be instrumental in Cavit's future.
ALTERNECARE(TM)'s product line joins Cavit's other two supplement lines, MD
SOLUTION(TM) and AMERICARE HEALTH PRODUCTS(TM). Its brand awareness and presence
in the retail market will assist the launch of Cavit's additional products and
lines.
An overview of ALTERNECARE(TM)'s products is available on its website:
www.alternecare.com
Cavit Sciences, Inc. ("Cavit") is a biotechnology company that has three
developed supplement lines with products that enhance, improve, maintain and
support the body by beneficially effecting various conditions and is engaged in
developing treatments and prevention for cancer, viral infections, opportunistic
infections, related diseases and the immune system. Product information and
updates will soon be available on Cavit's website. Additional information
regarding our supplement lines, treatment, development and Company information
is available on the Company's website at: www.cavitsciences.com
Statements contained herein that are not historical fact may be forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, that are subject to a
variety of risks and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those projected or
suggested in any forward-looking statements made by Cavit. These factors
include, but are not limited to: (i) the ability of Cavit to successfully raise
financing, (ii) the ability of Cavit to finalize its manufacturing and
distribution facilities, and (iii) the ability of Cavit to successfully
commercialize its products in certain markets. Additional factors that would
cause actual results to differ materially from those projected or suggested in
any forward-looking statements are contained in Cavit's filings with the
Securities and Exchange Commission, including those factors discussed under the
caption "Risk Factors" for Cavit on Form 10K-SB filed on April 18, 2008..
CONTACT:
Colm J. King, CEO (561) 544-6988
Cavit Sciences, Inc. www.cavitsciences.com

EX - 99 . 1 3 ex99 - 1 . txt PRESS RELEASE DATED 5 - 30 - 08 Exhibit 99 . 1 CAVIT SCIENCES , INC . ANNOUNCES ASSET PURCHASE AGREEMENT BOCA RATON , FL , MAY 30 , 2008 -- CAVIT SCIENCES , INC . ( " Cavit " ) ( OTCBB : CVIT ) announced today that it completed an Asset Purchase Agreement with Alternecare Health Products , Inc . ( " ALTERNECARE ( TM ) " ) on May 28 , 2008 . ALTERNECARE ( TM ) is an innovator and leader in combining rapid home diagnostics with therapeutic nutraceutical based solutions , has penetrated the retail market in the US and has initiated the process to establish itself in the e - commerce marketplace . Cavit acquired ALTERNECARE ( TM ) 's inventory , customer lists , existing relationships , trademark and website . Most importantly , Cavit acquired the consulting services of Ismael Gonzalez , ALTERNECARE ( TM ) 's President . Ismael has over 15 years of management experience in the natural products industry . He has held business development roles with top companies ranging from manufacturing to distribution . His business development expertise will be instrumental in Cavit 's future . ALTERNECARE ( TM ) 's product line joins Cavit 's other two supplement lines , MD SOLUTION ( TM ) and AMERICARE HEALTH PRODUCTS ( TM ) . Its brand awareness and presence in the retail market will assist the launch of Cavit 's additional products and lines . An overview of ALTERNECARE ( TM ) 's products is available on its website : www.alternecare.com Cavit Sciences , Inc . ( " Cavit " ) is a biotechnology company that has three developed supplement lines with products that enhance , improve , maintain and support the body by beneficially effecting various conditions and is engaged in developing treatments and prevention for cancer , viral infections , opportunistic infections , related diseases and the immune system . Product information and updates will soon be available on Cavit 's website . Additional information regarding our supplement lines , treatment , development and Company information is available on the Company 's website at : www.cavitsciences.com Statements contained herein that are not historical fact may be forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 , that are subject to a variety of risks and uncertainties . There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward - looking statements made by Cavit . These factors include , but are not limited to : ( i ) the ability of Cavit to successfully raise financing , ( ii ) the ability of Cavit to finalize its manufacturing and distribution facilities , and ( iii ) the ability of Cavit to successfully commercialize its products in certain markets . Additional factors that would cause actual results to differ materially from those projected or suggested in any forward - looking statements are contained in Cavit 's filings with the Securities and Exchange Commission , including those factors discussed under the caption " Risk Factors " for Cavit on Form 10K - SB filed on April 18 , 2008 . . CONTACT : Colm J . King , CEO ( 561 ) 544 - 6988 Cavit Sciences , Inc . www.cavitsciences.com